Leo knows P is the most important trial for IPIX t
Post# of 72447
(Total Views: 1021)
Posted On: 09/19/2017 8:31:50 PM
Leo knows P is the most important trial for IPIX this year with multiple BPs watching.
"We have currently completed enrollment of all subjects (up to 199). Subject recruitment was slower than projected due to competitive trials. In response, we added additional investigator sites. We expect to complete the trial by calendar year end 2017. Expenditures on Prurisol were approximately $4.6 million during the year ended June 30, 2017. We expect expenditures on Prurisol to increase in future reporting periods, as we complete the study. We have entered into multiple non-disclosure agreements with large pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship. "
I find this tidbit on B-UP interesting.
"We see significant opportunities in treating IBD with Brilacidin. Our development programs depending on available financial resources include new formulations (oral and foam type) with potential associated toxicology studies and clinical studies to be defined."
https://www.sec.gov/Archives/edgar/data/13552...ix_10k.htm
We know Leo just filed a $75 shelf registration so IPIX has the financial resources to develop the new formulations on their own. Is he hinting on a pending partnership?
"We have currently completed enrollment of all subjects (up to 199). Subject recruitment was slower than projected due to competitive trials. In response, we added additional investigator sites. We expect to complete the trial by calendar year end 2017. Expenditures on Prurisol were approximately $4.6 million during the year ended June 30, 2017. We expect expenditures on Prurisol to increase in future reporting periods, as we complete the study. We have entered into multiple non-disclosure agreements with large pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship. "
I find this tidbit on B-UP interesting.
"We see significant opportunities in treating IBD with Brilacidin. Our development programs depending on available financial resources include new formulations (oral and foam type) with potential associated toxicology studies and clinical studies to be defined."
https://www.sec.gov/Archives/edgar/data/13552...ix_10k.htm
We know Leo just filed a $75 shelf registration so IPIX has the financial resources to develop the new formulations on their own. Is he hinting on a pending partnership?
(4)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
